Duff & Phelps Investment Management Co. cut its position in Merck & Company, Inc. (NYSE:MRK) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,163 shares of the company’s stock after selling 2,170 shares during the period. Duff & Phelps Investment Management Co.’s holdings in Merck & were worth $1,997,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in MRK. HM Capital Management LLC grew its position in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after acquiring an additional 15 shares in the last quarter. RB Capital Management LLC boosted its position in Merck & by 0.5% during the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after buying an additional 23 shares during the period. Baystate Wealth Management LLC boosted its position in Merck & by 0.4% during the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after buying an additional 27 shares during the period. Bath Savings Trust Co boosted its position in Merck & by 0.5% during the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after buying an additional 28 shares during the period. Finally, Camelot Portfolios LLC boosted its position in Merck & by 0.4% during the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock valued at $494,000 after buying an additional 33 shares during the period. Institutional investors and hedge funds own 72.84% of the company’s stock.
Several equities analysts have recently commented on the stock. J P Morgan Chase & Co set a $70.00 price objective on shares of Merck & and gave the company a “buy” rating in a research note on Sunday, October 29th. Berenberg Bank reiterated a “hold” rating on shares of Merck & in a report on Wednesday, November 1st. BMO Capital Markets set a $70.00 price target on shares of Merck & and gave the company a “buy” rating in a report on Wednesday, October 18th. Zacks Investment Research downgraded shares of Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $74.00 price objective (down from $75.00) on shares of Merck & in a research note on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. Merck & has an average rating of “Hold” and an average price target of $67.07.
TRADEMARK VIOLATION WARNING: “Duff & Phelps Investment Management Co. Has $2 Million Stake in Merck & Company, Inc. (MRK)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/11/duff-phelps-investment-management-co-lowers-stake-in-merck-company-inc-mrk.html.
Shares of Merck & Company, Inc. (NYSE MRK) traded down $0.73 during mid-day trading on Friday, reaching $55.48. 16,743,801 shares of the company’s stock traded hands, compared to its average volume of 9,494,131. The company has a current ratio of 1.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.57. Merck & Company, Inc. has a one year low of $54.41 and a one year high of $66.80. The stock has a market capitalization of $153,140.61, a price-to-earnings ratio of 14.45, a PEG ratio of 2.42 and a beta of 0.78.
Merck & (NYSE:MRK) last posted its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. The company had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. Merck &’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 earnings per share. sell-side analysts anticipate that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.
In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.25% of the stock is owned by corporate insiders.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.